Today, Deshi made its official debut on the Hong Kong Stock Exchange, with its stock price skyrocketing by 121% at the opening bell. As the inaugural AI enterprise to go public following Hangzhou's ambition to become the "Pioneering City for AI Innovation and Development", Deshi has successfully bridged the gap in deploying B-side (business-side) AI large models within vertical sectors. This milestone marks the official launch of the commercialization journey for AI-powered medical foundation large models.

Deshi's IPO performance was nothing short of stellar, boasting an oversubscription rate of up to 1073 times. Even in the absence of cornerstone investors, the market enthusiastically embraced the offering, primarily driven by the sector's promising growth prospects and Deshi's leading market position. Financial data reveals that Deshi has entered a phase of commercialization marked by enhanced profitability and rapid expansion, with year-on-year revenue growth of 470% and an impressive gross profit margin of 75.9%. This revenue surge is largely attributable to the expansion of its core businesses, particularly its remarkable achievements in chromosome karyotype analysis services and foundation large model technology licensing.

Several leading industry players have already forged strategic partnerships with Deshi, propelling its transformation into a "digital new infrastructure provider." The capital raised through this IPO will primarily fuel Deshi's business expansion efforts. The company is poised to play a pivotal role in the hundred-billion-yuan medical imaging market, creating a win-win scenario that maximizes both commercial and social value.